{"disease":{"id":"neuroendocrine-tumor-carcinoid","name":"neuroendocrine tumor carcinoid"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT02628067","title":"Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158)","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1609,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":false},{"nct_id":"NCT03583528","title":"DOTATOC PET/CT for Imaging NET Patients","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":800,"lead_sponsor_name":"British Columbia Cancer Agency","has_results":false},{"nct_id":"NCT07389512","title":"Pharmaceutical Management in Targeted Radioligand Therapy","phase":"","overall_status":"RECRUITING","enrollment_count":600,"lead_sponsor_name":"Hospices Civils de Lyon","has_results":false},{"nct_id":"NCT02177773","title":"GA-68 DOTA-TOC of Somatostatin Positive Malignancies","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":300,"lead_sponsor_name":"University of California, San Francisco","has_results":true},{"nct_id":"NCT02754297","title":"Personalized PRRT of Neuroendocrine Tumors","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":275,"lead_sponsor_name":"CHU de Quebec-Universite Laval","has_results":false},{"nct_id":"NCT01619865","title":"Safety of 68Ga-DOTA-tyr3-Octreotide PET in Diagnosis of Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":223,"lead_sponsor_name":"Sue O'Dorisio","has_results":true},{"nct_id":"NCT07450287","title":"CardioNETPOL National Registry of Carcinoid Heart Disease","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":120,"lead_sponsor_name":"National Institute of Cardiology, Warsaw, Poland","has_results":false},{"nct_id":"NCT02826928","title":"Diagnostic Performances of Urine and Plasma 5-hydroxyindolacetic Acid (5HIAA) Values in Patients With Small-intestine Neuroendocrine Tumors","phase":"NA","overall_status":"COMPLETED","enrollment_count":116,"lead_sponsor_name":"CHU de Reims","has_results":false},{"nct_id":"NCT06472388","title":"Everolimus 5 mg vs 10 mg/Daily for Patients With Neuroendocrine Tumors","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":100,"lead_sponsor_name":"AC Camargo Cancer Center","has_results":false},{"nct_id":"NCT00688623","title":"RAMSETE: RAD001 in Advanced and Metastatic Silent Neuro-endocrine Tumors in Europe","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":73,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT04993261","title":"An Investigational Scan (Dual Energy CT) in Detecting Gastrointestinal Carcinoid Tumors","phase":"EARLY_PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":71,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT04017104","title":"Dynamic Whole Body Positron Emission Tomography/Computed Tomography Imaging","phase":"","overall_status":"UNKNOWN","enrollment_count":60,"lead_sponsor_name":"British Columbia Cancer Agency","has_results":false},{"nct_id":"NCT01253161","title":"Study of Pasireotide Long Acting Release (LAR) in Patients With Metastatic Neuroendocrine Tumors (NETs)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":29,"lead_sponsor_name":"H. Lee Moffitt Cancer Center and Research Institute","has_results":true},{"nct_id":"NCT05448157","title":"68Ga-DOTATOC Radio-Guided Surgery With β-Probe in GEP-NET","phase":"","overall_status":"UNKNOWN","enrollment_count":20,"lead_sponsor_name":"European Institute of Oncology","has_results":false},{"nct_id":"NCT04073017","title":"Enterade in Carcinoid/Non-Carcinoid Syndrome Neuroendocrine Tumor Patients With Quality of Life Limiting Bowel Frequency","phase":"NA","overall_status":"TERMINATED","enrollment_count":11,"lead_sponsor_name":"Vanderbilt-Ingram Cancer Center","has_results":false},{"nct_id":"NCT03722511","title":"Evaluating an Amino Acid Based Medical Food w/ Diarrhea in Carcinoid Syndrome & Other NETs","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":10,"lead_sponsor_name":"Lowell Anthony, MD","has_results":false},{"nct_id":"NCT04140409","title":"Sandostatin (Octreotide LAR) May Lead to Clinical Improvement Through Receptor Occupation Optimisation","phase":"PHASE4","overall_status":"TERMINATED","enrollment_count":10,"lead_sponsor_name":"Cliniques universitaires Saint-Luc- Université Catholique de Louvain","has_results":false},{"nct_id":"NCT03420521","title":"Nivolumab With Ipilimumab in Subjects With Neuroendocrine Tumors","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":9,"lead_sponsor_name":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","has_results":true},{"nct_id":"NCT02859064","title":"Study of Lanreotide in Patients With Metastatic Gastrointestinal Neuroendocrine Tumors Who Are Undergoing Liver-directed Radioembolization With Yttrium-90 Microspheres","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":6,"lead_sponsor_name":"SCRI Development Innovations, LLC","has_results":true},{"nct_id":"NCT05987176","title":"Comparison of Adjuvant Treatment With 177Lu-DOTATATE to Best Supportive Care in Patients After Resection of Neuroendocrine Liver Metastases","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":1,"lead_sponsor_name":"Imperial College London","has_results":false},{"nct_id":"NCT04915144","title":"177Lu-DOTATOC for the Treatment of Patients With Somatostatin Receptor Positive NETs","phase":"PHASE2","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"British Columbia Cancer Agency","has_results":false}],"total":21},"guidelines":[],"source":"Drug Landscape verified database"}